Uterine Fibroids Treatment Market- Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The Uterine Fibroids Treatment Market is projected to register a CAGR of 4.5% during the forecast period (2022-2027).

The coronavirus pandemic has caused major changes worldwide, especially in healthcare systems. The COVID-19 pandemic resulted in the cancellation of all elective procedures. While patients with uterine fibroids are not at risk in the same way as Critical Limb Ischemia patients are, their quality of life has been adversely impaired in some cases. As a result, restrictions on access to elective therapies, imposed either to decrease virus cross-transmission or to prepare the hospital structure to aid infected patients, have forced women to live with discomfort and ineffective temporary treatments. As a result, restrictions on access to elective therapies, imposed either to decrease virus cross-transmission or to prepare the hospital structure to aid infected patients, have forced women to live with discomfort and ineffective temporary treatments.

The market is likely to be driven by the high prevalence of uterine fibroids among women worldwide, increased patient preference for less invasive procedures, and the adoption of technologically sophisticated technologies. Excessive menstrual flow, pelvic pain, infertility, and frequent urination are all symptoms of uterine fibroid (UF), a benign tumor of the smooth muscle cells that grow in the uterus. Even though the etiology is unknown, race, age, genetic susceptibility, premenopausal status, hypertension, overweight, and diet are all risk factors. Per the article published by Contemporary OB/GYN in February 2022 on "A look at the current state of uterine fibroid care," over 70% of women are estimated to develop uterine fibroids by age 50.

Furthermore, the market is predicted to develop due to patients' preference for minimally invasive and non-invasive fibroids operations. Smaller incisions reduce post-operative pain and speed recovery, resulting in the widespread use of these procedures. Several major firms are investing in R&D to bring new minimally invasive and non-invasive surgical devices to market. One of the incision-less techniques physicians commonly suggest is MR-guided Focused Ultrasound (MRgFUS) for treating uterine fibroids. The gadget emits ultrasonic beams, which heat and remove specific tissue from the uterine cavity during this treatment. As this is a non-invasive procedure, there are little to no side effects, and patients can resume normal activities within a few days. As a result of the increased demand for such operations due to their little pain, efficacy, low risk of infection, and quick recovery compared to open surgeries, the market for uterine fibroids treatment devices is expected to rise.

Expanding uterine fibroids awareness and education beyond gynecologic professionals and promoting individualized patient treatment through collaborative decision-making were also flagged as ways to address unmet needs. For example, in November 2021, Minerva Surgical, Inc. (a women's health company specializing in treating AUB) announced the introduction of a new consumer education experience for women. Furthermore, investigating novel non-hormonal medical therapy could lead to advanced fibroids treatment options that do not affect fertility. Upregulation of vitamin D, for example, could protect against fibroid growth while having no harmful influence on ovarian function. Furthermore, Bayer invests in uterine fibroids as part of its clinical development program.

Hence, the availability of advanced products, surgical techniques, and initiatives by various market players contribute to the overall market growth.

Key Market Trends

The Hysterectomy Segment is Expected to Hold a Major Market Share in the Uterine Fibroids Treatment Market

The worldwide impact of COVID-19 continues to be felt as hospitals in all countries reduce elective and non-urgent cases to allow staffing and resources to be deployed elsewhere. As per the article published in 2021 on “Gynecological laparoscopic surgeries in the era of COVID-19 pandemic: a prospective study”, A joint statement issued by the American Association of Gynecologic Laparoscopists (AAGL), American College of Obstetricians & Gynaecologists (ACOG), and other organizations advised the suspension of elective surgery, shifting the focus to emergency and cancer surgery.

The rising number of hysterectomy surgical procedures is one of the main drivers of market growth. Furthermore, this method is the most popular and well-proven permanent treatment for uterine fibroids. As a result, the category will likely grow as the number of related surgeries increases. As per the article published in November 2020 on “Hysterectomy in the United States, by Verywell Health, according to the Centers for Disease Control and Prevention (CDC), about 600,000 hysterectomies are performed in the United States each year. According to the American College of Obstetricians and Gynecologists, around a third of all women will have a hysterectomy by age 60.

For severe menstrual bleeding, ablation procedures are a frequent surgical treatment. The endometrial lining of the uterus is surgically abated in this minimally invasive procedure. Endometrial ablation requires no incisions and can be performed in the doctor’s office without general anesthesia. Furthermore, after the endometrial ablation operation, pregnancy is conceivable. As a result, the advantages afforded by ablation procedures are projected to propel the segment forward.

North America is Expected to Hold a significant share in the market and is expected to do the Same in the Forecast Period.

The pandemic of COVID-19 has a significant impact on gynecologic surgery. The American College of Surgeons suggested delaying all non-essential invasive surgeries in March 2020. According to a December 2021 study article titled "Analysis of COVID-19 Response and Impact on Gynecologic Surgery at a Large Academic Hospital System," 1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline. The most common procedure in 2020 was a hysterectomy, whereas surgery for endometriosis and uterine fibroids saw the greatest decline in volume. Many patients had significant delays in receiving gynecologic surgical care during the peak pandemic.

The presence of well-established healthcare facilities in the region increased government initiatives, and an increase in hysterectomy-related surgical procedures/hospital visits are all driving the market in North America. Furthermore, the presence of major important companies like Medtronic, Stryker, and CooperSurgical, Inc., as well as the availability of technologically improved goods, all contribute to the region's market growth. Furthermore, the region's adoption of uterine fibroids treatment devices is fueled by the region's easy access to healthcare technologies and strong distribution channels.

Various governments and commercial groups are working to raise awareness of early fibroids detection and treatment through various efforts. In the United States, for example, July is designated as "Fibroids Awareness Month." In recent years, more initiatives have raised awareness about uterine fibroids. The White Dress Project, HealthyWomen.org, Fibroids Project, and Center for Innovative GYN Care are just a few famous programs. The White Dress Project aims to raise awareness about fibroids by generating funding for research and educating women on the basics. This initiative encourages and supports women to join and share their stories. In addition, the Fibroids Project is an online community and website dedicated to assisting women in becoming fibroids-free. They aim to provide information about current research, initiatives, and procedures to both women and medical professionals. Growing awareness among women about uterine fibroids treatment and activities is expected to promote market growth.

Competitive Landscape

The uterine fibroids treatment market is fragmented and competitive and consists of several major players. Some players operating in the market are Myovant Sciences GmbH; Gynesonics, Boston Scientific Corporation, INSIGHTEC, Hologic, Inc., Karl Storz Gmbh, Minerva Surgical, Inc., Pfizer, Inc., Abbvie, Inc., and ObsEva. Market players are adopting various strategies such as mergers, acquisitions, and new product developments to remain competitive.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support